EuroBiotech:​​ ​​More​​ ​​Articles​​ ​​of​​ ​​Note

A pile of newspapers
Novo Seeds, MorphoSys and NeuroSearch were in the news this week.

> Targovax revealed that a supply interruption has disrupted clinical development of ONCOS-102. The setback has pushed back the data readouts from a mesothelioma trial and a pair of partnered studies by up to six months. A trial of ONCOS-102 in melanoma is still on track to deliver data late next year. Release

> Genfit kicked off pediatric development of its NASH candidate elafibranor. The action follows the European Medicines Agency’s approval of a pediatric development plan for the drug. Genfit has begun the program with juvenile toxicology studies. Release

> The Danish Supreme Court found NeuroSearch guilty of market manipulation. The charges date back to the publication of top-line data from a Phase III trial in 2010. A lower court ruled against NeuroSearch in 2014, but the company appealed. Having lost again, NeuroSearch’s board is assessing the future of the company. Release

> Novo Seeds invested in Merozyne Therapeutics. The fund joined with Almi Invest to put up SEK 6.3 million ($684,000) to fund research into a potential treatment for congenital muscular dystrophy. Merozyne’s approach is based on the autophagy process, the discovery of which won a Nobel Prize this year. Release

> Innate Pharma posted more data from a Phase I/II trial combining lirilumab and Bristol-Myers Squibb’s Opdivo. The new data show that 41% of participants with PD-L1 expression levels of 1% or more responded to the combination. Just shy of one-quarter of the whole trial population responded. Release

> MorphoSys raised €115 million ($123 million) in a private placement. Some of the money will go toward a Phase III trial of MorphoSys’ anti-CD19 antibody MOR208 in diffuse large B cell lymphoma. Release